EirGen Pharma Oncology Product Eir-014 successfully submitted in the US

EirGen Pharma are pleased to announce that their oncology molecule "Eir-014" was submitted to the Food & Drug Administration (FDA) in June 2009. This product is a chemotherapy drug that is given as a treatment for some types of cancer. It is most commonly used to treat Hodgkin`s lymphoma and brain tumours.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.